Tianwei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tianwei Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Congyi Zhang
Department of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China
1 shared publication - Guiping Han
Department of Pathology, Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China
1 shared publication - Ming Liang
First department of infection, second affiliated hospital of Harbin medical university, Harbin, China
1 shared publication - Shan Yu
Department of Pathology, Second Affiliated Hospital of Harbin Medical University, 150086 Harbin, Heilongjiang, China
1 shared publication - Sheng Tai
Department of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publication - Shizhuan Huang
Department of hepatic surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China
1 shared publication
Latest Publications
- Open Access
- 21 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 21
The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System
Drug delivery system (DDS) realizes the drug delivery process through the drug carrier. As an important part of DDS, the selection of the drug carrier material is extremely critical, which requires the carrier material to possess excellent biocompatibility and targeting and not affect the pharmacological action of the drug. As one of the endogenous extracellular vesicles, exosomes are 30–100 nm in diameter, which are considered a new generation of a natural nanoscale delivery system. Exosomes secreted by different types of cells carry signaling molecules (such as proteins and nucleic acid) playing an important role in cell behaviors. Owing to their ability to specialize in intercellular communication, exosomes provide a distinctive method to deliver therapeutic drugs to target cells. In this concept, exosomes as the natural liposomes carry endogenous biomolecules, have excellent biocompatibility, and could be loaded with cargo both in vivo and in vitro. In addition, modifications by genetic and/or chemical engineering to part of the exosome surface or complement the desired natural effect may enhance the targeting with drug loading capability. Notably, exosomes weakly react with serum proteins prolonging cargo half-life. Overall, exosomes as natural carriers integrate the superiority of synthetic nanocarriers and cellular communication while precluding their limitations, which provides novel and reliable methods for drug delivery and treatment. Our review focuses on the therapeutic potentials and clinical values of exosomes as a carrier of drug delivery system in multiple diseases, including cancer, nervous, immune, and skeletal system diseases.
- 21 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 21
Open AccessThe Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System
Drug delivery system (DDS) realizes the drug delivery process through the drug carrier. As an important part of DDS, the selection of the drug carrier material is extremely critical, which requires the carrier material to possess excellent biocompatibility and targeting and not affect the pharmacological action of the drug. As one of the endogenous extracellular vesicles, exosomes are 30–100 nm in diameter, which are considered a new generation of a natural nanoscale delivery system. Exosomes secreted by different types of cells carry signaling molecules (such as proteins and nucleic acid) playing an important role in cell behaviors. Owing to their ability to specialize in intercellular communication, exosomes provide a distinctive method to deliver therapeutic drugs to target cells. In this concept, exosomes as the natural liposomes carry endogenous biomolecules, have excellent biocompatibility, and could be loaded with cargo both in vivo and in vitro. In addition, modifications by genetic and/or chemical engineering to part of the exosome surface or complement the desired natural effect may enhance the targeting with drug loading capability. Notably, exosomes weakly react with serum proteins prolonging cargo half-life. Overall, exosomes as natural carriers integrate the superiority of synthetic nanocarriers and cellular communication while precluding their limitations, which provides novel and reliable methods for drug delivery and treatment. Our review focuses on the therapeutic potentials and clinical values of exosomes as a carrier of drug delivery system in multiple diseases, including cancer, nervous, immune, and skeletal system diseases.